COLORECTALONCOLOGYProgressNote§§Date:April172025Pt44MwithRECTALBLEEDINGandweightloss§colonoscopy02/2025showed5.8cmsemi-obstructingmass~atdescendingcolonBx:moderatelydifferentiatedadenocarcinoma

CEAlevel:124ng/mL(elevated)CTAbdomen/pelvis03/2025|mass6.2cmdescendingcolon+pericoliciymphnodes+2×LIVERMETS(segment5:3.4cm,segment8:2.1cm)CHESTCT:clear§noLungmetsSTAGE~cT3N2M1a,IVA

PATHOLOGY~Colonoscopy:Adenocarcinoma,moderatedifferentiation,tubulararchitecture,invasionthroughmuscularispropria

MOLECULAR|NGStesting(Guardant360)completed03/2024:MSI:MSS(microsateliitestable)dMMR:pMMR(profiicientmismatchrepair)TMB:7mut/Mb(TMB-Low)KRAS~G12DmutationdetectedVAF52%NRAS:wtBRAF:V600EwtPI3KCA:E545Kmutation(VAF18%)APC:truncatingmutationc.4012C>T(VAF44%)TP53:R273Hmutation(VAF39%)SMAD4:loss(homozygousdeletion)§RAS/RAFwildtype?NO~KRASmutated!

PtEvaluation:ECOG~performance~status:2(symptomatic,ambulatory>50%,occasional~assistance)weight||loss:18kgover4monthsAnemia:Hgb8.2g/dL(requiredirontransfusion2units)RenalfunctionCrCl:55mL/min(mildimpairment)Liverfunctiontests~elevated:ALT88,AST92,alkphos234

TREATMENT~EnrolIedinBEACON-CRCtrial(NCT02928224)triplettherapy:encorafenib+binimetinib+cetuximabSTARTEDApri120,2025||NOTE:UsuallyforBRAFV600Emutatedbutthispatient~KRASG12D?!PROTOCOLDEVIATION~actuallyenrolledinKODIAK-C RCtrial(NCT05198336)adagrasib(KRASG12Cinhibitor)+cetuximab~WAIT~wrongmutation~shouldbeG12CbutpatienthasG12D!

CORRECTtrialafterreview:CodeBreaK300(NCT05198180)~sotorasib+panitumumabforKRASG12D~actuallypatientenrolledhere05/01/2025afterprotocolclarification

Cycle1-2(May/June2025):§toleratedmoderately,Grade2acneiformrash(cetuximab-related),Grade2diarrhea,Grade1fatigue

RestagingCT07/2025:Liverlesions~INCREASED!segment5now4.8cm(was3.4cm),segment8now3.1cm(was2.1cm)=PROGRESSION~primarycolontumor:slightlysmaller5.1cm

MIXED~RESPONSE?Primarydecreasing,Metsincreasingleadinvestigatorcalled"ProgressiveDisease"per~RECIST~1.1criteria

PatientexperiencedGrade3||ELECTROLYTE~abnormalityhypomagnesemia(Mg0.9mg/dL)requireIVrepletion+severedehydrationfromdiarhea~hospita1izationfor5days~trialTREATMENTHELD

ResumedtrialCycle408/2025reduceddose~sotorasib480mgdaily(from960mg)

NextCT09/2025:NEW~lungmetastases!rightlowerlobe:1.3cmnoduleleftupperlobe:0.9cmnoduleLivermets:stable~Stage§IVB(M1bnow~multipleorgans)Discontinuedfromtrial~progressivedisease

NEWSECONDLINE~startedFOLFIRI+bevacizumab09/15/2025Cycle1-3:toleratedwell,grade1neutropeniaCycle4(11/2025):developedGrade3neutropenicfever~hospitalized~broadspectrumantibiotics(meropenem)G-CSFadministered,growth~factorsupportCycle5:doseREDUCEDirinotecan~from180mg/m2to135mg/m2

RestagingCT12/2024:Partialresponse~Lungmets:decreased(0.8cmand0.6cm)Livermets:decreased(segment5:2.9cm,segment8:1.7cm)Primary:3.8cmCEA:68ng/mL(decreasedfrom124)

Patientdiscussed~forsurgicaLresectionofprimarytumor+livermetastasectomy§surgeonevaiuationpending~potentiallyresectableafterfurther~downsizing

TrialNOTE:Eligible~forpost-surgeryADJUVANTtrialCOSMIC-CRC-312adjuvantimmunotherapy+targetedtherapycombination~ifresectionsuccessfuI
